Cargando…
Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters’ Levels, but Has No Effect on Body Composition Parameters
BACKGROUND: Psoriasis is frequently accompanied by metabolic syndrome. Effect of anti-tumor necrosis factor therapies on increases in body weight is well-known. Data on the effects of interleukin-17 inhibitors are limited. Authors determined the effect of anti-interleukin-17 therapies on the body co...
Autores principales: | Piros, Éva Anna, Szabó, Ákos, Rencz, Fanni, Brodszky, Valentin, Wikonkál, Norbert, Miheller, Pál, Horváth, Miklós, Holló, Péter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228146/ https://www.ncbi.nlm.nih.gov/pubmed/34207504 http://dx.doi.org/10.3390/life11060535 |
Ejemplares similares
-
Impact of Interleukin-17 Inhibitor Therapy on Arterial Intima-media Thickness among Severe Psoriatic Patients
por: Piros, Éva Anna, et al.
Publicado: (2021) -
A Rasch model analysis of two interpretations of ‘not relevant’ responses on the Dermatology Life Quality Index (DLQI)
por: Rencz, Fanni, et al.
Publicado: (2021) -
Antidrug antibody formation during tumor necrosis factor α inhibitor treatment of severe psoriatic patients in the real-life practice
por: Herszényi, Krisztina, et al.
Publicado: (2019) -
The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa
por: Bató, Alex, et al.
Publicado: (2021) -
Is the trend of increasing use of patient-reported outcome measures in medical device studies the sign of shift towards value-based purchasing in Europe?
por: Weszl, Miklós, et al.
Publicado: (2019)